IGC Pharma (IGC) investor relations material

Clinical trial progress and drug development

• Lead asset IGC-AD1, a cannabinoid-based therapy for agitation in Alzheimer's, is in phase II CALMA trial with 70% enrollment and expected completion by mid-year.

• Additional assets include TGR-63 targeting amyloid plaque, and early-stage programs for tau neurodegeneration and metabolic dysfunction.

• The CALMA trial is expanding sites in the US, Canada, and Colombia, using educational outreach to boost enrollment.

• Top-line data from the CALMA trial is expected within one to two months after trial completion, potentially by late summer.

• The drug shows promise for rapid reduction in agitation and sleep disturbance, with potential disease-modifying effects.

AI platform and technology initiatives

• Developing MINT-AD, an AI tool for Alzheimer's risk stratification and cognitive decline prediction, using global datasets to minimize bias.

• MINT-AD will enter beta testing in the US within months, with plans for global deployment and partnerships with community centers.

• The AI platform aims to provide accessible risk assessment without costly PET scans, supporting non-pharmacological interventions.

Market opportunity and strategic positioning

• Alzheimer's affects 50 million globally, with agitation impacting 76% of patients; even 1% market penetration could yield $1 billion in revenue.

• The drug's fast-acting, sleep-improving, and potential disease-modifying properties differentiate it in a large, underserved market.

• Post-phase II, options include partnerships, sale, or further trials targeting cognition and sleep, with potential deal values up to $3-4 billion.